



PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/1-00

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page

1

of

**Complete if Known**

Application Number	10/006,881
Filing Date	December 10, 2001
First Named Inventor	REITER, et al.
Art Unit	1648
Examiner Name	Not Yet Assigned
Attorney Docket Number	20695C-002300US

RECEIVED  
JUL 09 2003  
TECH CENTER 1600/2900**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
SBC	AA	WO	91/09935	A1	07-11-1991	—	abstract only (English)	<input type="checkbox"/>

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SBC	AB	Kistner et al., "Development of a novel influenza vaccine derived from a continuous cell line", <i>Linz</i> 18:1: 50-54 XP001146190 (2001). <i>English abstract only. SBC 1/16/04</i>	
SBC	AC	Kistner et al., "Novel Mammalian Cell (Vero) Derived Influenza Virus Vaccine: Development, Characterization and Individual Scale Production", <i>Wiener Klinische Wochenschrift</i> 111:5: 207-214, XP000909353 (1999).	
SBC	AD	Barrett et al., "Large-Scale Production and Purification of a Vaccinia Recombinant-Derived HIV-1 gp160 and Analysis of Its Immunogenicity", <i>Aids Research and Human Retroviruses</i> 5:2: 159-172, XP001064669 (1989).	
SBC	AE	Percheson et al., "A Phase I, Randomized Controlled Clinical Trial to Study the Reactogenicity and Immunogenicity of a New Split Influenza Vaccine Derived from a Non-Tumorigenic Cell Line", <i>Developments in Biological Standardization</i> 98: 127-132, XP009008177 (1999).	
SBC	AF	Sharkey et al., "Ross River Virus Glycoprotein-Pseudotyped Retroviruses and Stable Cell Lines for Their Production", <i>Journal of Virology</i> 75:6: 2853-2859, XP002235508 (2001).	

Examiner Signature	Stacy B. Chen	Date Considered	January 16, 2004
-----------------------	---------------	--------------------	------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.